# TITLE PAGE

**Title: Lifestyle intervention in gastroesophageal reflux disease**

**Short title:** Lifestyle intervention in GERD

**Word count:** 3,834 (maximum 6,000 words, including figure and table legends, and references)

**Authors:** Eivind Ness-Jensen, M.D., Ph.D.1,2; Kristian Hveem, M.D., Ph.D.2; Hashem El-Serag, M.D., M.P.H1,3; and Jesper Lagergren, M.D., Ph.D.1,4

1Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

2HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway

3Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA

4Section of Gastrointestinal Cancer, Division of Cancer Studies, King’s College London, United Kingdom

**Grant support:** ENJ is supported by the Norwegian and Swedish Research Councils. KH has no grant support covering his wages. HES is supported by NIH K24 DK04-107 and the Houston VA Health Services Research and Development Center of Excellence (HFP90-020). JL is supported by grants from the Swedish Research Council.

**Abbreviations (alphabetically):** ACG – American College of Gastroenterology

AGA – American Gastroenterological Association

BMI – body mass index

CAG – Canadian Association of Gastroenterology

CI – confidence interval

GERD – gastroesophageal reflux disease

HUNT – The Nord-Trøndelag health study

OR – odds ratio

PPI – proton pump inhibitor

RCT – randomized clinical trial

**Corresponding author:** Eivind Ness-Jensen, M.D., Ph.D.

Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, NS 67, 171 76 Stockholm, Sweden

E-mail: eivind.ness-jensen@ki.se

Telephone: 0047 918 60 549

Fax number: 0046 8 51776280

**Disclosures:** No relevant conflicts of interest exist

**Author contributions:** ENJ was involved in study concept and design, acquisition and interpretation of literature, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. HES was involved in study concept and design, acquisition and interpretation of literature, and critical revision of the manuscript for important intellectual content. KH and JL were involved in study concept and design, interpretation of literature, and critical revision of the manuscript for important intellectual content.

# ABSTRACT (word count 240, maximum 260 words)

**Background & Aims** Gastroesophageal reflux disease (GERD) affects up to 30% of adults in Western populations and is increasing in prevalence. GERD is associated with lifestyle factors, particularly obesity and tobacco smoking, which also threatens the general health. GERD carries risk of several adverse outcomes and there is widespread use of potent acid-inhibitors which are associated with long-term adverse effects. The aim of this systematic review was to assess the role of lifestyle intervention in the treatment of GERD.

**Methods** Literature searches were performed in PubMed (from 1946), EMBASE (from 1980), and the Cochrane Library (no start date) to October 1, 2014. Meta-analyses, systematic reviews, randomized clinical trials (RCTs) and prospective observational studies were included.

**Results** Weight loss was followed by decreased time with esophageal acid exposure in two RCTs (from 5.6% to 3.7% and from 8.0% to 5.5%, respectively), and reduced reflux symptoms in prospective observational studies. Tobacco smoking cessation reduced reflux symptoms in normal weight individuals in a large prospective cohort study (odds ratio 5.67). In RCTs, late evening meals increased time with supine acid exposure compared to early meals (5.2% points change), and head of the bed elevation decreased time with supine acid exposure compared to a flat position (from 21% to 15%).

**Conclusions** Weight loss and tobacco smoking cessation should be recommended to GERD patients who are obese and smoke, respectively. Avoiding late evening meals and head of the bed elevation is effective in nocturnal GERD.

**Keywords:** GERD; heartburn; acid regurgitation; therapy; treatment

# MAIN TEXT (word count 3,834, maximum 6,000 words, including figure and table legends, and references)

Gastroesophageal reflux disease (GERD), defined by at least weekly symptoms of heartburn or acid regurgitation, is increasingly common.1 The prevalence in adults ranges from 30% in some Western populations to below 10% in East Asian populations, and the incidence is about 5/1000 person-years in Western populations.1 GERD is associated with reduced health-related quality of life,2 decreased work productivity3 and increased risk of esophageal adenocarcinoma.4 The annual incidence of esophageal adenocarcinoma is increasing worldwide, from 3.5% in Scotland to 8.1% in Hawaii, which parallels the increasing prevalence of GERD.5 In addition, GERD diagnostic tests and treatments carry high societal costs.6

The pathophysiology of GERD is dominated by functional and anatomic defects at the gastroesophageal junction, including reduced pressure and increased reflux episodes associated with transient relaxations of the lower esophageal sphincter and formation of hiatal hernia which promotes and facilitates reflux.7-9 Esophageal motility and salivary bicarbonate contribute to esophageal acid clearance and buffering, respectively, and reduce acid contact time in the esophagus.10,11 Visceral obesity increases the pressure over the gastroesophageal junction, thus facilitating reflux,12 while tobacco smoking reduces the lower esophageal sphincter pressure and salivary bicarbonate secretion, which facilitates reflux and decreases acid buffering, respectively.13,14

The main established risk factors of GERD are heredity, obesity and tobacco smoking.15-18 High dietary fiber intake and moderate physical exercise seem to reduce this risk,18 while sex and age do not strongly influence the risk of GERD.19,20 Obesity is of particular interest since it is increasing in prevalence in parallel with GERD, and several studies have shown an increased risk of GERD and esophagitis with obesity, especially abdominal obesity.21,22

GERD is typically diagnosed by the cardinal symptoms heartburn or acid regurgitation23 and symptom resolution following acid-inhibition with a proton pump inhibitor (PPI).24 If symptoms do not resolve, endoscopy is usually performed and mucosal erosions (esophagitis) or peptic strictures are diagnostic of GERD.25 Endoscopy can also reveal Barrett’s esophagus, a premalignant columnar metaplasia, and esophageal adenocarcinoma. If endoscopy is normal, esophageal pH-measurement can still reveal pathologic acid reflux (pH <4).26 The pH-measurement can be combined with impedance-measurement to detect reflux of weakly acidic or non-acidic liquid and gas, which can cause reflux symptoms refractory to acid inhibition.27

The treatment of GERD is primarily by medication with antacids, H2-receptor antagonists and PPIs, while surgery (typically with fundoplication) is used in selected patients. Recent evidence shows that long-term PPI medication is hampered by adverse effects. This includes secondary hypergastrinemia and rebound acid hypersecretion, inducing reflux symptoms at withdrawal of PPI medication;28 increased risk of enteric infections and community acquired pneumonia, probably due to increased gastric pH causing reduced host defence;29,30 and increased risk of hip and vertebral fractures, probably due to malabsorption of calcium.31

This review addresses lifestyle intervention in the treatment of GERD and compares existing evidence with current guidelines.

# METHODS

Systematic literature searches on lifestyle intervention in GERD were performed in MEDLINE using PubMed from 1946 and EMBASE using OvidSP from 1980 to October 1, 2014. In addition, the Cochrane Library was searched, last time October 1, 2014. The searches included thesaurus terms (MeSH in MEDLINE and EMTREE in EMBASE): “gastroesophageal reflux”, “heartburn”, “peptic esophagitis” (EMBASE)/”esophagitis, peptic” (MEDLINE) and “non-erosive reflux disease” (EMBASE). Randomized clinical trials (RCTs), prospective observational studies, and meta-analyses and systematic reviews of RCTs or observational studies of GERD patients were included. The searches were limited to the English language and research on adult humans. The evidence of interventions was graded using the American Heart Association’s guidelines: Multiple populations evaluated, data derived from multiple RCTs or meta-analyses (**Level A**); limited populations evaluated, data derived from a single RCT or non-randomized studies (**Level B**); and very limited populations evaluated, only consensus opinion of experts, case studies or standard of care (**Level C**).

# RESULTS

### Literature searches

Literature searches on lifestyle intervention identified 15 original studies that met the inclusion criteria (**Table and eTable**). In addition, one previous systematic review on lifestyle intervention and one previous systematic review on conservative and surgical treatment for obesity in GERD were identified.32,33 No relevant Cochrane reviews were identified. Three management guidelines were assessed: the Canadian Association of Gastroenterology (CAG) consensus (2005);24 the American Gastroenterological Association (AGA) medical position statement and technical review (2008);34,35 and the American College of Gastroenterology (ACG) guideline (2013).36

### Lifestyle interventions

Lifestyle interventions in GERD have traditionally included avoidance of foods that may precipitate reflux episodes and heartburn (e.g., coffee, alcohol, chocolate, peppermint, citrus, carbonated drinks and spicy foods) and behavioral changes with weight loss, smoking cessation, head of the bed elevation, avoiding large meals and avoiding recumbence after meals or meals before bedtime.34,35 The previous systematic review on lifestyle intervention in GERD concluded that only weight loss and head of the bed elevation were effective for GERD, while the systematic review on conservative and surgical treatment for obesity concluded that dietary and lifestyle intervention may improve GERD in obese patients.32,33 However, new supportive evidence has emerged.

### Weight loss

Three RCTs in severely obese individuals compared weight loss by gastric balloon distension with sham treatment combined with dietary guidance, physical exercise and behavioral therapy, and showed reduced esophageal acid exposure with weight loss.37-39 In the first RCT, including 17 patients, 3 of 5 patients with pathological pH-measurements got normalized pH-measurements with weight loss of 31.3-44.0 kg after 4 months.37 In the second RCT, 23 patients with a mean weight loss of 11.2 kg within 13 weeks had decreased time with esophageal pH <4 (from 5.60% to 3.72%, *P* <0.05).38 Moreover, there was a strong correlation between decreased waist circumference and acidic reflux time (*r*=0.78, *P*=0.000).38 These results were supported by the third RCT of 17 sham treated patients, where mean weight loss of 12.5 kg within 13 weeks improved time with upright pH <4 (from 8.0% to 5.5%, *P* <0.05).39

A larger RCT compared obese participants randomized to a structured weight loss program (n=167) or a telephone-based group conference on weight management (n=165). The prevalence of reflux symptoms decreased (from 37% to 15%, *P* <0.01) and the symptom score improved (Reflux Disease Questionnaire, *P* <0.01) after 6 months of weight loss (mean body mass index (BMI) decreased from 34.7 to 30.2), irrespective of treatment group.40

These results were confirmed in 2 uncontrolled prospective cohort studies of GERD patients.41,42 A study of 8 extremely obese patients (mean BMI 43.5) showed significant improved total time with pH <4 (from 5.1% to 2.5%, *P*=0.022) and reflux symptoms score (Distress Subscale of Gastroesophageal Reflux Disease Symptom Assessment Scale from 1.28 to 0.72, *P*=0.0004) after 4 days on a very low-carbohydrate diet and a mean weight loss of 1.7 kg.41 Moreover, a study of 34 patients with mean BMI of only 23.5, reflux symptoms and either normal endoscopy or low grade esophagitis also showed significant correlation between weight loss after dietary advice (mean BMI decrease 1.7) and reflux symptom score (modified DeMeester questionnaire, *r*=0.548, *P* <0.001).42

Two large prospective population-based cohort studies showed that weight reduction dose-dependently decreased reflux symptoms.43,44 The Nurses’ Health Study, an observational cohort study of 10,545 women, showed a dose-dependently reduced risk of reflux symptoms among women who had decrease in BMI compared to women with no BMI change (odds ratio (OR) 0.64, 95% confidence interval (CI) 0.42-0.97 with >3.5 units decrease in BMI, *P* for trend <0.001).43 The HUNT study, a prospective population-based cohort study of 29,610 participants also showed a dose-dependent association between weight loss and the chance of losing reflux symptoms (OR 2.42, 95% CI 1.88-3.11 with >3.5 units decrease in BMI, *P* for trend <0.001). In this study, decrease in BMI was also associated with an increased chance of losing reflux symptoms with medical treatment (OR 1.98, 95% CI 1.45-2.72 with >3.5 units decrease in BMI and no or less than weekly medication compared to OR 3.96, 95% CI 2.03-7.65 with >3.5 units decrease in BMI and at least weekly medication).44

Challenging these results, a small RCT showed that weight loss (mean 10.8 kg) did not have significant effects on symptoms, esophagitis or pH-measurements in obese patients (mean BMI=31.4) with GERD who were randomized to a low-caloric diet (430 kcal/day) for 6 months (n=10) or not (n=9).45 In addition, a prospective population-based cohort study of 637 individuals showed no association between weight loss and reflux symptoms, but since weight loss was self-reported it might be overestimated.46

### Tobacco smoking cessation

A prospective population-based cohort study (the HUNT study) of 29,610 participants showed that smoking cessation was associated with decreased severe reflux symptoms in normal weight individuals on medical treatment, compared to participants who continued smoking daily (OR 5.67, 95% CI 1.36-23.64).47 However, there was no similar association in overweight (BMI 25.0-29.9) or obese (BMI ≥30.0) individuals (OR 1.24, 95% CI 0.57-2.71 and OR 1.29, 95% CI 0.53-3.17, respectively). A possible explanation for these findings is that GERD pathophysiology in obese individuals is strongly dictated by weight, while smoking plays a minor role, but smoking is a more important factor in non-obese individuals.

### Dietary interventions

A RCT showed no influence of weight loss following a 6 month period of low-caloric diet (430 kcal/day) on GERD.45 However, a small non-randomized study of 8 severely obese patients (mean BMI=43.5) who lost weight (1.7 kg) on a 4-day very low-carbohydrate diet (<20g/day) showed a decreased total time with pH <4 (from 5.1% to 2.5%, *P*=0.022) and reflux symptoms score (from 1.28 to 0.72, *P*=0.0004).41

A crossover RCT of 30 patients randomized to a late meal (2 hours before bedtime) or an early meal (6 hours before bedtime) showed more pH-verified supine reflux after the late evening meal (mean change 5.2%, *P*=0.002).48

A RCT that compared patients using a dietary fiber product (n=15) with placebo (n=15) for 2 weeks, showed an increased number of days without heartburn (mean 1.87 and 0.73, respectively, *P* <0.05) and reduced severity score (mean 7.7 and 13.3, respectively, *P* <0.05) in the fiber group.49

A systematic review based on observational studies showed no evidence of carbonated beverages promoting GERD.50

Regarding other potential dietary interventions there were no studies meeting the search criteria.

### Head of bed elevation

A crossover RCT of 15 GERD participants, showed that elevation of the head of the bed by a 10 inch wedge decreased esophageal pH <4 time compared to a flat position (15% and 21%, respectively, *P* <0.05).51

# DISCUSSION

RCTs have shown reduced reflux symptoms and esophageal acid exposure with weight loss,37-40 findings supported by well-designed observational studies showing a dose-dependent decreased presence of reflux symptoms following weight reduction. A large prospective observational study showed reduced reflux symptoms with tobacco smoking cessation in normal weight individuals.47 RCTs also showed that early evening meals48 and head of the bed elevation51 decreased the esophageal acid exposure time, and dietary fiber decreased reflux symptoms.49

Based on the present review, we believe that the evidence of lifestyle modifications in GERD has been strengthened compared to the statements in the three current treatment guidelines.24,34-36 The CAG guideline concludes that lifestyle modifications are ineffective for frequent or severe reflux symptoms and that data are insufficient to support lifestyle modifications in mild reflux.24 The AGA guideline recommends weight loss in obese GERD patients and elevation of the head of the bed in patients experiencing reflux symptoms when recumbent, while other lifestyle modifications should be individually tailored.34,35 The ACG guideline supports avoidance of meals two to three hours before bedtime, in addition to weight loss and head of bed elevation. However, it does not recommend elimination of food that can trigger reflux.36

We believe that patients suffering from GERD should be recommended to lose weight if they are obese, that tobacco smoking cessation and increased dietary fiber should be encouraged and that late evening meals should be avoided and head of the bed elevation recommended for patients with supine reflux. Based on the pathophysiologic mechanisms, weight loss in obese patients will presumably reduce the increased pressure on the gastroesophageal junction, reducing reflux.12 Smoking cessation will normalize the lower esophageal sphincter pressure and salivary bicarbonate production.13,14 It is speculated that dietary fiber expand with water to form a barrier to the acid rising into the esophagus.49 Avoiding late evening meals and head of the bed elevation will reduce nighttime supine reflux.48,51 Any effect of a very low-carbohydrate diet is uncertain, as the study included cannot separate the effects of weight loss from those of the diet.41 However, a small case series showed a significant and almost immediate resolution of GERD symptoms in obese individuals initiating a very low-carbohydrate diet.52 Lifestyle interventions, especially weight loss and tobacco smoking cessation, are also beneficial from other perspectives, including low economic costs, no harmful side-effects and overall health benefits. In addition, observational studies have shown that weight loss and tobacco smoking cessation are associated with improved success with medical treatment.44,47

Extensive data exists on the effects of acid inhibiting medication in GERD, opposed to only few and heterogeneous RCTs or observational studies of lifestyle intervention. Commercial interests are probably the main reason for this imbalance of studies. Non-commercial funding should focus on performing larger RCTs on lifestyle interventions to verify these results and get more reliable conclusion. Nevertheless, the available evidence is reasonably consistent and supported by the pathophysiology and epidemiology. The effects of these interventions on reflux symptoms, acid exposure and endoscopic findings should be assessed in future studies. As obesity and smoking are risk factors of GERD, reduced prevalence of these exposures in the populations could also reduce the incidence of GERD.

# CONCLUSIONS

Recent evidence supports lifestyle intervention in the treatment of GERD. These include weight loss, tobacco smoking cessation, avoiding late evening meals, and head of the bed elevation. Meanwhile, the awareness of adverse effects of medical treatment has increased, questioning long-term and continuous PPI therapy, at least in mild GERD.

# REFERENCES

1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut.* 2014;63(6):871-880.

2. Ronkainen J, Aro P, Storskrubb T, et al. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population--the Kalixanda study. *Aliment. Pharmacol. Ther.* 2006;23(12):1725-1733.

3. Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. *Aliment. Pharmacol. Ther.* 2006;24(2):259-272.

4. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N. Engl. J. Med.* 1999;340(11):825-831.

5. Edgren G, Adami HO, Weiderpass E, Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. *Gut.* 2013;62(10):1406-1414.

6. Mason J, Hungin AP. Review article: gastro-oesophageal reflux disease--the health economic implications. *Aliment. Pharmacol. Ther.* 2005;22 Suppl 1:20-31.

7. Mittal RK, Balaban DH. The esophagogastric junction. *N. Engl. J. Med.* 1997;336(13):924-932.

8. Hershcovici T, Mashimo H, Fass R. The lower esophageal sphincter. *Neurogastroenterol. Motil.* 2011;23(9):819-830.

9. Kessing BF, Conchillo JM, Bredenoord AJ, Smout AJ, Masclee AA. Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease. *Aliment. Pharmacol. Ther.* 2011;33(6):650-661.

10. Penagini R, Bravi I. The role of delayed gastric emptying and impaired oesophageal body motility. *Best Pract. Res. Clin. Gastroenterol.* 2010;24(6):831-845.

11. Orlando RC. Pathophysiology of gastroesophageal reflux disease. *J. Clin. Gastroenterol.* 2008;42(5):584-588.

12. Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. *Gastroenterology.* 2006;130(3):639-649.

13. Kahrilas PJ, Gupta RR. The effect of cigarette smoking on salivation and esophageal acid clearance. *J. Lab. Clin. Med.* 1989;114(4):431-438.

14. Dennish GW, Castell DO. Inhibitory effect of smoking on the lower esophageal sphincter. *N. Engl. J. Med.* 1971;284(20):1136-1137.

15. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut.* 2005;54(5):710-717.

16. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. *Ann. Intern. Med.* 2005;143(3):199-211.

17. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. *JAMA.* 2003;290(1):66-72.

18. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. *Gut.* 2004;53(12):1730-1735.

19. Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. *Am. J. Epidemiol.* 2005;162(11):1050-1061.

20. Becher A, Dent J. Systematic review: ageing and gastro-oesophageal reflux disease symptoms, oesophageal function and reflux oesophagitis. *Aliment. Pharmacol. Ther.* 2011;33(4):442-454.

21. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. *JAMA.* 2010;303(3):235-241.

22. Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. *Clin. Gastroenterol. Hepatol.* 2013;11(11):1399-1412 e1397.

23. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am. J. Gastroenterol.* 2006;101(8):1900-1920; quiz 1943.

24. Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. *Can. J. Gastroenterol.* 2005;19(1):15-35.

25. Tefera L, Fein M, Ritter MP, et al. Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease? *Am. Surg.* 1997;63(10):933-936.

26. Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. *Gastroenterology.* 1996;110(6):1982-1996.

27. Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. *Am. J. Gastroenterol.* 2007;102(3):668-685.

28. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. *Gastroenterology.* 2009;137(1):80-87, 87 e81.

29. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. *Aliment. Pharmacol. Ther.* 2011;34(11-12):1269-1281.

30. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. *Aliment. Pharmacol. Ther.* 2010;31(11):1165-1177.

31. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. *Am. J. Gastroenterol.* 2011;106(7):1209-1218; quiz 1219.

32. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. *Arch. Intern. Med.* 2006;166(9):965-971.

33. De Groot NL, Burgerhart JS, Van De Meeberg PC, de Vries DR, Smout AJ, Siersema PD. Systematic review: the effects of conservative and surgical treatment for obesity on gastro-oesophageal reflux disease. *Aliment. Pharmacol. Ther.* 2009;30(11-12):1091-1102.

34. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology.* 2008;135(4):1383-1391, 1391 e1381-1385.

35. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. *Gastroenterology.* 2008;135(4):1392-1413, 1413 e1391-1395.

36. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am. J. Gastroenterol.* 2013;108(3):308-328; quiz 329.

37. Mathus-Vliegen LM, Tytgat GN. Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension. *Eur. J. Gastroenterol. Hepatol.* 1996;8(7):635-640.

38. Mathus-Vliegen EM, Tygat GN. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. *Scand. J. Gastroenterol.* 2002;37(11):1246-1252.

39. Mathus-Vliegen EM, van Weeren M, van Eerten PV. Los function and obesity: the impact of untreated obesity, weight loss, and chronic gastric balloon distension. *Digestion.* 2003;68(2-3):161-168.

40. Singh M, Lee J, Gupta N, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. *Obesity.* 2013;21(2):284-290.

41. Austin GL, Thiny MT, Westman EC, Yancy WS, Jr., Shaheen NJ. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. *Dig. Dis. Sci.* 2006;51(8):1307-1312.

42. Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. *Scand. J. Gastroenterol.* 1999;34(4):337-340.

43. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA, Jr. Body-mass index and symptoms of gastroesophageal reflux in women. *N. Engl. J. Med.* 2006;354(22):2340-2348.

44. Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. *Am. J. Gastroenterol.* 2013;108(3):376-382.

45. Kjellin A, Ramel S, Rossner S, Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. *Scand. J. Gastroenterol.* 1996;31(11):1047-1051.

46. Cremonini F, Locke GR, 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohort. *Neurogastroenterol. Motil.* 2006;18(11):987-994.

47. Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population-based cohort study: the HUNT study. *Am. J. Gastroenterol.* 2014;109(2):171-177.

48. Piesman M, Hwang I, Maydonovitch C, Wong RK. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? *Am. J. Gastroenterol.* 2007;102(10):2128-2134.

49. DiSilvestro RA, Verbruggen MA, Offutt EJ. Anti-heartburn effects of a fenugreek fiber product. *Phytother. Res.* 2011;25(1):88-91.

50. Johnson T, Gerson L, Hershcovici T, Stave C, Fass R. Systematic review: the effects of carbonated beverages on gastro-oesophageal reflux disease. *Aliment. Pharmacol. Ther.* 2010;31(6):607-614.

51. Hamilton JW, Boisen RJ, Yamamoto DT, Wagner JL, Reichelderfer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. *Dig. Dis. Sci.* 1988;33(5):518-522.

52. Yancy WS, Jr., Provenzale D, Westman EC. Improvement of gastroesophageal reflux disease after initiation of a low-carbohydrate diet: five brief case reports. *Altern. Ther. Health Med.* 2001;7(6):120, 116-129.

# TABLE

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table. Lifestyle intervention in gastroesophageal reflux disease (GERD)** | | | | | | | | | | | | | | | | |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  | **Comparison with current guidelines** | | | | |
| **Category** |  | **Study** |  | **Design** |  | **Intervention** |  | **Findings** |  | **Level of evidencea** |  | **CAGb (2005)24** |  | **AGAc (2008)34,35** |  | **ACGd (2013)36** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Weight loss** |  | Mathus-Vliegen et al. 199637 |  | RCTe |  | Gastric balloon vs. sham treatment |  | Normalization of pH-measurements in 3 of 5 with weight loss |  | A |  | Lifestyle modifications are ineffective for frequent or severe symptoms, but may be beneficial if obvious dietary precipitants, obesity or tobacco smoking |  | Weight loss in obese patients; Head of the bed elevation if symptoms when recumbent; Other lifestyle modifications tailored to the individual patient |  | Weight loss recommended for GERD patients with overweight or recent weight gain; Head of bed elevation and avoidance of meals 2 – 3 hour before bedtime recommended if nocturnal GERD; Routine global elimination of food that can trigger reflux not recommended |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Mathus-Vliegen et al. 200238 |  | RCTe |  | Gastric balloon vs. sham treatment |  | Reduced acid exposure in sham group (the effect of mere weight loss) |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Mathus-Vliegen et al. 200339 |  | RCTe |  | Gastric balloon vs. sham treatment |  | Reduced acid exposure in sham group (the effect of mere weight loss) |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Singh et al. 201340 |  | RCTe |  | Structured weight loss program vs. telephone-based group conference |  | Decreased symptom prevalence and score in both groups |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Austin et al. 200641 |  | Non-randomized prospective study |  | Very low-carbohydrate diet |  | Decreased acid exposure and symptom score |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Fraser-Moodie et al. 199942 |  | Non-randomized prospective study |  | Dietary advice |  | Decreased symptom score |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Jacobson et al. 200643 |  | Prospective population-based cohort study |  | No intervention |  | Dose-dependent decrease in symptom prevalence |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Ness-Jensen et al. 201344 |  | Prospective population-based cohort study |  | No intervention |  | Dose-dependent decrease in symptoms, improved medical treatment success |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Kjellin et al. 199645 |  | RCTe |  | Low-caloric diet vs. control |  | No effect on symptoms, endoscopic findings or acid exposure |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Cremonini et al. 200646 |  | Prospective population-based cohort study |  | No intervention |  | No association with symptoms |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Tobacco smoking cessation** |  | Ness-Jensen et al. 201447 |  | Prospective population-based cohort study |  | No intervention |  | Decreased symptoms in normal weight individuals |  | B |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Dietary interventions** |  | Kjellin et al. 199645 |  | RCTe |  | **Low-caloric diet vs. control** |  | No effect on symptoms, endoscopic findings or acid exposure |  | B (no effect) |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Austin et al. 200641 |  | Non-randomized prospective study |  | **Very low-carbohydrate diet** |  | Decreased acid exposure and symptom score |  | B |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Piesman et al. 200748 |  | RCTe |  | **Late vs. early evening meal** |  | Decreased acid exposure with early evening meal |  | B |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | DiSilvestro et al. 201149 |  | RCTe |  | **Dietary fiber vs. placebo** |  | Decreased symptom prevalence and score with dietary fiber |  | B |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Johnson et al. 201050 |  | Systematic review of observational studies |  | **Carbonated beverages** |  | No effect on GERD |  | B (no effect) |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Head of the bed elevation** |  | Hamilton et al. 198851 |  | RCTe |  | Head of bed elevation vs. flat position |  | Decreased acid exposure with head of bed elevation |  | B |  |  |  |
|  | | | | | | | | | | | | | | | | |
| a**A** - Multiple populations evaluated, data derived from multiple randomized clinical trials or meta-analyses; **B** - Limited populations evaluated, data derived from a single randomized clinical trial or non-randomized studies; **C** - Very limited populations evaluated, only consensus opinion of experts, case studies, or standard of care. bCanadian Association of Gastroenterology. cAmerican Gastroenterological Association. dAmerican College of Gastroenterology. eRandomized clinical trial. | | | | | | | | | | | | | | | | |